MBRX (Moleculin Biotech) Total Current Assets: $10.96 Mil (As of Mar. 2026)


MBRX Moleculin Biotech Inc MBRX
30 GF Score
Price $3.57
! 1 Warning Sign
View Full Analysis

What is Moleculin Biotech Total Current Assets?

Moleculin Biotech MBRX +9.51% 30 Total Current Assets is $10.96 Mil as of Mar. 2026. GuruFocus rates MBRX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Moleculin Biotech's total current assets for the quarter that ended in Mar. 2026 was $10.96 Mil.

Moleculin Biotech  (NAS:MBRX) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Moleculin Biotech's Liquidation Value for the quarter that ended in Mar. 2026 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=10.317-8.18+0.75 * 0+0.5 * 0
=2.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moleculin Biotech Total Current Assets Related Terms

Moleculin Biotech Total Current Assets Historical Data

* Premium members only.

The historical data trend for Moleculin Biotech's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moleculin Biotech Total Current Assets Chart

Moleculin Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 72.50 45.60 26.27 5.19 9.69

Moleculin Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.34 9.08 7.89 9.69 10.96
MBRX
30GF Score
Moleculin Biotech Inc MBRX
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moleculin Biotech Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Moleculin Biotech's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=8.878+0.007+0+0.801
=9.69

Moleculin Biotech's Total Current Assets for the quarter that ended in Mar. 2026 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=10.317+0.009+0+0.635
=10.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of $10.96 Mil mean?
Moleculin Biotech (MBRX) has a Total Current Assets of $10.96 Mil as of Mar. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Moleculin Biotech and its competitors.
Is Moleculin Biotech's Total Current Assets too high?
Moleculin Biotech's current Total Current Assets is $10.96 Mil. Overall, Moleculin Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Moleculin Biotech's Total Current Assets compare to JAGX and BCDA?
Moleculin Biotech's Total Current Assets of $10.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Moleculin Biotech and its competitors. Moleculin Biotech's current Total Current Assets is $10.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moleculin Biotech stock overvalued right now?
Moleculin Biotech (MBRX) has a current Total Current Assets of $10.96 Mil. The current Total Current Assets is $10.96 Mil. Moleculin Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Moleculin Biotech (MBRX), the current Total Current Assets is $10.96 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Moleculin Biotech Business Description

Other Exchanges 0K2H:UK
Address 5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
30GF Score

Get the complete analysis for MBRX

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.57
Price